Advanced NSCLC Clinical Trial
— POSITIVEOfficial title:
Physical Exercise Program in Lung Cancer Patients With Non-operable Disease Undergoing Palliative Treatment
Verified date | August 2018 |
Source | German Cancer Research Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The investigators plan to evaluate, in a randomized, controlled phase III trial in patients
with advanced non-small cell lung cancer (NSCLC), the effects of a 24-week exercise
intervention program (EIP) on quality of life, physical functioning and immune function
parameters. Eligible patients (n=250) will be enrolled in the Clinic for Thoracic Diseases,
Heidelberg, over a time period of two years and followed up for a total of 12 months.
Patients will be randomized either to EIP plus Care Management Phone Calls (CMPC) versus CMPC
alone (besides a proper symptom and side effect management CMPC ensures the potential
influence of social contacts that can be anticipated for the patients in the intervention
group).
Our primary aims are to investigate whether a combination of a partly supervised (in- and
outpatient) and partly home-based endurance and resistance training improves quality of life
(QoL) and lowers levels of fatigue (evaluation via the standardized and validated
questionnaires FACT-L and MFI). In addition we propose to evaluate the effects of EIP on
tumor specific immune responses. Biomarkers of immune function will be measured by cellular
immunity and cytokine and chemokine panels.
Further secondary outcomes include measurement of anxiety, depression and demoralization,
physical performance parameters (e.g. improvement in walk distance, muscle strength), as well
as overall and progression free survival analyses.
The study builds on a previous feasibility study of a 8 weeks exercise intervention trial in
patients with advanced NSCLC with the results being utilized in the design of the here
proposed trial.
The investigators hypothesize that patients randomized in the exercise intervention group
will show improved QoL and reduced fatigue, as well as improved physical functioning and
increased tumor specific immune responses.
Status | Completed |
Enrollment | 232 |
Est. completion date | March 2018 |
Est. primary completion date | March 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - NSCLC stage IIIB/IV - receiving systemic treatment (palliative radiotherapy accepted) - BMI > 18 - ECOG (Eastern Cooperative Oncology Group) performance status = 2 - signed informed consent Exclusion Criteria: - serious active infection (i.e. requiring an iv antibiotic, antifungal or antiviral agent) - inability to walk - immobility (more than two days) - previously untreated (non-irradiated or non-resected) symptomatic brain metastases;permitted are: (1) previously treated brain metastases [radiotherapy, surgery, dexamethasone dosage 8 mg per day, anti-epileptic therapy]; (2) asymptomatic brain metastases without additional therapy requirement - severe neurologic impairment (e.g. apoplectic insult, Morbus Parkinson, pareses of extremities) - severe cardiac impairment (e.g. cardiac insufficiency NYHA (New York Heart Association) > III, myocardial infarction within the last three months, unexplained syncopal events, severe cardiac arrhythmias, high grade aortic stenosis) - severe respiratory insufficiency - uncontrolled pain - abuse of alcohol or drugs reducing compliance to the study - bone metastasis inducing skeletal fragility - any circumstance that would impede ability to give informed consent or adherence to study requirements. |
Country | Name | City | State |
---|---|---|---|
Germany | Thoracic Oncology Clinic for Thoracic Diseases | Heidelberg | Baden-Württemberg |
Lead Sponsor | Collaborator |
---|---|
German Cancer Research Center | National Center for Tumor Diseases, Heidelberg, University Hospital Heidelberg |
Germany,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Adverse Events | Safety analyses will be based on Adverse Events (AE´s), Severe Adverse Events (SAE´s), and Suspected Unexpected Serious Adverse Reaction (SUSARs) recorded during the study. Of particular interest are AEs, SAEs and SUSARs deemed to be potentially causally related to the endurance and resistance training. | baseline until 6 month after enrolement | |
Other | Translational Program / Immunology | Quantification (Q) of immune cells: Multicolor flow cytometry from cryopreserved Peripheral Blood Mononuclear Cell (PBMC), CD (cluster of differentiation) 4+ and CD 8+ T cells, effector, naïve and activated T cells, regulatory T cells (Treg) and their functional subsets, natural killer cells, B cells, monocytes and monocyte-derived myeloid suppressor cells will be assessed. Q. of tumor antigen reactive effector/memory T cells: Will be done by interferon gamma Enzyme Linked Immuno Spot Assays from PBMC using a panel of defined tumor antigens presented by generated autologous dendritic cells as antigen presenting cells and purified T cells as responder cells. Detection of tumor reactive Treg: Will be done by established Treg specificity assay based on the increased suppressive activity of specifically activated regulatory T cells. Q. of key immune effector molecules: Will be done for app. 14 different cytokines and chemokines from cryopreserved serum samples. |
baseline, 3 & 6 month after enrolement | |
Primary | QoL: Physical Well-Being (FACT-L) | The FACT-L (Functional Assessment of Cancer Therapy-Lung) questionnaire comprises of 36 items and deter-mines the quality of life in patients with lung cancer. It is separated in the subcategories "physical well-being" (PRIMARY OUTCOME), "emotional well-being", "social well-being", "functional well-being and disease-specific items". It is widely used in clinical studies and was already applied in exercise intervention studies in lung cancer patients | assessed after 12 weeks of enrolement | |
Primary | General Fatigue (MFI) | The MFI (Multidimensional Fatigue Inventory) questionnaire (20 items) evaluates the extent of chronic fatigue and is divided into the 5 subscales "general fatigue", "physical fatigue", "mental fatigue", "reduced motivation" and "reduced activity". The MFI questionnaire is widely used in oncological studies and an adequate number of comparative samples exists. | assessed after 12 weeks of enrolement | |
Secondary | Physical Performance (endurance and strength capacity) | 6-Minute Walk Test (endurance capacity) The 6 minute walk test is feasible and safe to determine patients physical capacity. Patients are instructed to walk in 6 min. as many meters as possible with oxygen saturation and pulse rate being measured concomitantly. Hand-held Dynamometry (isometric strength capacity) The hand-held dynamometry is a standardized instrument to measure muscular strength. In the study 6 major muscle groups of upper and lower extremities will be assessed for their isometric power. |
assessed every 3 month after enrolement until month 12 | |
Secondary | Psychosocial Parameters (e.g. depression, anxiety, demoralization) | PHQ(Ultra-Brief Patient Health Questionnaire)-4 : The PHQ-4 (Ultra-Brief Patient Health Questionnaire) questionnaire is a short instrument comprising of 4 items to detect the extent of depression and anxiety. It provides sufficient diagnostic accuracy for major depression and can be used as a screening instrument in cancer populations. DS (Demoralization Scale) The demoralization scale (DS) is a relatively new developed questionnaire to detect the extent of existential distress in cancer patients. The German version was validated in 2011 and comprises of 24 questions. The results of the validation showed that the concept of demoralization is a useful instrument to describe the different states of existential distress and the individual incapacity to cope effectively with stressful situations. |
assessed every 3 month after enrolement until month 12 | |
Secondary | Overall survival | for the period of 1 year after enrolement | ||
Secondary | progression-free survival | for the period of 1 year after enrolement |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02133196 -
T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
|
Phase 2 | |
Recruiting |
NCT00813332 -
Second-line Therapy Study of Combined Chemotherapy and Endostar to Patients With Non-Small Cell Lung Cancer(NSCLC)
|
Phase 4 | |
Completed |
NCT03215810 -
Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer
|
Phase 1 | |
Recruiting |
NCT04982224 -
Study of REGN5093-M114 (METxMET Antibody-Drug Conjugate) in Adult Patients With Mesenchymal Epithelial Transition Factor (MET) Overexpressing Advanced Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT05609578 -
Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation
|
Phase 2 | |
Not yet recruiting |
NCT04992858 -
Ningetinib in Advanced NSCLC Skipping Mutations With MET Exon 14 Skipping Mutations
|
Phase 2 | |
Active, not recruiting |
NCT03127449 -
AST2818 in Advanced Non-Small Cell Lung Cancer With EGFR Mutations
|
N/A | |
Not yet recruiting |
NCT06356675 -
A Single-arm Pilot Study of Tislelizumab Combined With Anlotinib in Patients With Advanced NSCLC With Driver-negative After Progression to Immunotherapy
|
Phase 4 | |
Completed |
NCT03074175 -
Plasma miRNAs Predict Radiosensitivity of Different Fractionation Regimes in Palliative Radiotherapy for Advanced Non-small Cell Lung Cancer:Multicenter Controlled Study.(RadmiR-01)
|
N/A | |
Terminated |
NCT05106335 -
A Study to Evaluate Camrelizumab Combined With Famitinib as Subsequent Therapy in Patients With Advanced NSCLC
|
Phase 3 | |
Not yet recruiting |
NCT04229121 -
Clinical Sensitivity Verification Study of Circulating Tumor Cells Gene Mutation Detection From Advanced NSCLC Patients
|
||
Completed |
NCT05219162 -
Real-World Study on Gene Profile in Patients With Advanced NSCLC Who Progressed on First-Line Osimertinib Therapy(GPS).
|
Phase 4 | |
Not yet recruiting |
NCT05859217 -
A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1)
|
Phase 2 | |
Recruiting |
NCT03062800 -
Study of Thalidomide in Treatment of Advanced Nsclc (Dream-003)
|
Phase 2 | |
Active, not recruiting |
NCT04043195 -
Nivolumab and Ipilimumab in Combination With Immunogenic Chemotherapy for Patients With Advanced NSCLC
|
Phase 1/Phase 2 |